-
Jul 2, 2025 Apotex receives Health Canada approval for Aflivu™, a biosimilar to Eylea®, available in pre-filled syringe and vial formats
-
May 20, 2025 Apotex publishes 2024 Sustainability Report, highlighting progress and achievements in environmentally sustainable manufacturing, responsible business practices, and social impact
-
May 1, 2025 Apotex announces grant to Foundation for Mother and Child Health to promote maternal health with CAD $100,000 in annual funding
-
Mar 27, 2025 Apotex announces $100,000 in annual funding to advance maternal and infant health in Mexico
-
Feb 24, 2025 Apotex licenses exclusive Canadian rights to Qutenza® from Grünenthal
-
Feb 13, 2025 Apotex announces grant to Healthy Mothers, Healthy Babies Coalition of Broward County to promote maternal health with $242,000 in annual funding
-
Feb 5, 2025 Apotex acquires US rights to PROVIGIL® (modafinil) and NUVIGIL® (armodafinil)
-
Feb 5, 2025 Apotex, through its specialty pharma division, Searchlight, expands branded dermatology portfolio through the in-licensing of the Canadian rights to SEYSARA® (sarecycline) and FINJUVE™ (finasteride)
-
Feb 3, 2025 Apotex enters the growing Canadian health and wellness sector through the acquisition of CanPrev, a leading Canadian natural health company
-
Jan 31, 2025 Voluntary Recall of five (5) lots of APO-QUETIAPINE XR (quetiapine fumarate extended-release tablets)
-
Dec 10, 2024 Apotex announces launch of the Apotex Global Health Access Fund to promote health equity with $250,000 in annual funding to the Rexdale Community Health Centre
-
Oct 16, 2024 Voluntary Recall of twenty-seven (27) lots of APO-AMITRIPTYLINE (Amitriptyline Hydrochloride Tablets USP)
-
Aug 7, 2024 Apotex expands ophthalmic franchise through the acquisition of Canadian rights to APP13007 (clobetasol propionate ophthalmic suspension, 0.05%), a novel steroid for ophthalmology
-
Jul 3, 2024 Apotex Further Expands Oncology Franchise Through the Acquisition of Canadian Rights to Toripalimab
-
Jun 3, 2024 Apotex Completes Acquisition of Searchlight, a leading Canadian-based Specialty Innovative Branded Pharmaceutical Company
-
Apr 2, 2024 Apotex to Acquire Searchlight Pharma, a Canadian Specialty Branded Pharmaceutical Leader
-
Feb 16, 2024 Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products
-
Aug 9, 2023 Voluntary Recall of seven (7) lots of APO-ACYCLOVIR (Acyclovir Tablets Apotex Standard)
-
Aug 9, 2023 Voluntary Recall of three (3) lots of APO-AMITRIPTYLINE (Amitriptyline Hydrochloride Tablets USP)
-
Apr 3, 2023 SK Capital completes acquisition of Apotex, a global leader in affordable pharmaceuticals
Media inquries
Have a question for our media team? Fill out our inquiries form, and we’ll get back to you as soon as possible.
Latest news
-
Jul 2, 2025
Apotex receives Health Canada approval for Aflivu™, a biosimilar to Eylea®, available in pre-filled syringe and vial formats
Apotex Inc., the Canadian-based global health company, today announced that Health Canada has approved Aflivu™ (aflibercept), a biosimilar to Eylea®, indicated for the treatment of neovascular (wet) age-related macular degeneration, macular edema secondary to central or branch retinal vein occlusion, treatment of diabetic macular edema, and treatment of myopic choroidal neovascularization.
-
May 20, 2025
Apotex publishes 2024 Sustainability Report, highlighting progress and achievements in environmentally sustainable manufacturing, responsible business practices, and social impact
Apotex's 2024 Sustainability Report underscores our commitment to advancing health and unlocking new possibilities through partnerships, while championing sustainability and responsible business practices. "As we continue to execute our Journey of Health growth strategy, our focus on sustainability ensures that we are meeting the needs of patients, physicians, and pharmacists, and contributing positively to the environment and society. This report reflects our dedication to these values, and to transparency, accountability, and long-term value creation," said Allan Oberman, President & CEO, Apotex.
-
May 1, 2025
Apotex announces grant to Foundation for Mother and Child Health to promote maternal health with CAD $100,000 in annual funding
Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, yesterday announced a grant through the Apotex Global Health Access Fund to the Foundation for Mother and Child Health ("FMCH") in Mumbai, India to support programs that promote maternal health and address child malnutrition.